Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention
Abstract Background Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help identifying diabetic patients at higher risk deserving tailored antipla...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0952-8 |
id |
doaj-70e691d528d3444a9d2f8e4266d31c11 |
---|---|
record_format |
Article |
spelling |
doaj-70e691d528d3444a9d2f8e4266d31c112020-11-25T03:58:27ZengBMCCardiovascular Diabetology1475-28402019-11-011811910.1186/s12933-019-0952-8Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary interventionAnnunziata Nusca0Dario Tuccinardi1Claudio Proscia2Rosetta Melfi3Silvia Manfrini4Antonio Nicolucci5Antonio Ceriello6Paolo Pozzilli7Gian Paolo Ussia8Francesco Grigioni9Germano Di Sciascio10Unit of Cardiac Sciences, Campus Bio-Medico University of RomeUnit of Endocrinology and Diabetes Department of Medicine, Campus Bio-Medico University of RomeCardiology Department, Liverpool Heart and Chest Hospital NHS TrustUnit of Cardiac Sciences, Campus Bio-Medico University of RomeUnit of Endocrinology and Diabetes Department of Medicine, Campus Bio-Medico University of RomeCardiovascular and Diabetes Department, IRCCS MultiMedicaCardiovascular and Diabetes Department, IRCCS MultiMedicaUnit of Endocrinology and Diabetes Department of Medicine, Campus Bio-Medico University of RomeUnit of Cardiac Sciences, Campus Bio-Medico University of RomeUnit of Cardiac Sciences, Campus Bio-Medico University of RomeUnit of Cardiac Sciences, Campus Bio-Medico University of RomeAbstract Background Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help identifying diabetic patients at higher risk deserving tailored antiplatelet and/or glucose lowering strategies is unknown. We aimed to investigate the relationship between GV, HbA1c levels and platelet reactivity in patients with type 2 diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI). Methods Platelet reactivity was measured in type 2 DM patients using VerifyNow P2Y12 assay. HPR was defined as P2Y12 Reaction Unit (PRU) > 240. GV was expressed through mean amplitude of glycaemic excursions (MAGE) and coefficient of variance (CV) by using the iPro™ continuous glucose recorder. Results Thirty-five patients (age 70 ± 9 years, 86% male, mean HbA1c 7.2 ± 1.0%) on clopidogrel therapy were enrolled. HbA1c was independently associated with HPR (OR 7.25, 95% CI 1.55–33.86, p = 0.012). Furthermore, when factored into the model, GV indexes provided independent (OR 1.094, 95% CI 1.007–1.188, p < 0.034) and additional (p < 0.001) diagnostic significance in identifying diabetic patients with HPR. Conclusions Glyco-metabolic state significantly correlates with HPR in well-controlled type 2 DM patients on clopidogrel therapy. HbA1c identifies patients at higher thrombotic risk but the highest diagnostic accuracy is achieved by combining GV and HbA1c. Whether individualized antithrombotic and glucose-lowering therapies based on the assessment of these parameters may reduce the incidence of thrombotic events in patients undergoing PCI should be further investigated.http://link.springer.com/article/10.1186/s12933-019-0952-8Glycated haemoglobinGlycaemic variabilityContinuous glucose monitoringPlatelet reactivityPercutaneous coronary intervention |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Annunziata Nusca Dario Tuccinardi Claudio Proscia Rosetta Melfi Silvia Manfrini Antonio Nicolucci Antonio Ceriello Paolo Pozzilli Gian Paolo Ussia Francesco Grigioni Germano Di Sciascio |
spellingShingle |
Annunziata Nusca Dario Tuccinardi Claudio Proscia Rosetta Melfi Silvia Manfrini Antonio Nicolucci Antonio Ceriello Paolo Pozzilli Gian Paolo Ussia Francesco Grigioni Germano Di Sciascio Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention Cardiovascular Diabetology Glycated haemoglobin Glycaemic variability Continuous glucose monitoring Platelet reactivity Percutaneous coronary intervention |
author_facet |
Annunziata Nusca Dario Tuccinardi Claudio Proscia Rosetta Melfi Silvia Manfrini Antonio Nicolucci Antonio Ceriello Paolo Pozzilli Gian Paolo Ussia Francesco Grigioni Germano Di Sciascio |
author_sort |
Annunziata Nusca |
title |
Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention |
title_short |
Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention |
title_full |
Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention |
title_fullStr |
Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention |
title_full_unstemmed |
Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention |
title_sort |
incremental role of glycaemic variability over hba1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention |
publisher |
BMC |
series |
Cardiovascular Diabetology |
issn |
1475-2840 |
publishDate |
2019-11-01 |
description |
Abstract Background Diabetic patients with on-treatment high platelet reactivity (HPR) show an increased risk of thrombotic events. Whether measuring glycated haemoglobin (HbA1c) levels and/or glycaemic variability (GV) may help identifying diabetic patients at higher risk deserving tailored antiplatelet and/or glucose lowering strategies is unknown. We aimed to investigate the relationship between GV, HbA1c levels and platelet reactivity in patients with type 2 diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI). Methods Platelet reactivity was measured in type 2 DM patients using VerifyNow P2Y12 assay. HPR was defined as P2Y12 Reaction Unit (PRU) > 240. GV was expressed through mean amplitude of glycaemic excursions (MAGE) and coefficient of variance (CV) by using the iPro™ continuous glucose recorder. Results Thirty-five patients (age 70 ± 9 years, 86% male, mean HbA1c 7.2 ± 1.0%) on clopidogrel therapy were enrolled. HbA1c was independently associated with HPR (OR 7.25, 95% CI 1.55–33.86, p = 0.012). Furthermore, when factored into the model, GV indexes provided independent (OR 1.094, 95% CI 1.007–1.188, p < 0.034) and additional (p < 0.001) diagnostic significance in identifying diabetic patients with HPR. Conclusions Glyco-metabolic state significantly correlates with HPR in well-controlled type 2 DM patients on clopidogrel therapy. HbA1c identifies patients at higher thrombotic risk but the highest diagnostic accuracy is achieved by combining GV and HbA1c. Whether individualized antithrombotic and glucose-lowering therapies based on the assessment of these parameters may reduce the incidence of thrombotic events in patients undergoing PCI should be further investigated. |
topic |
Glycated haemoglobin Glycaemic variability Continuous glucose monitoring Platelet reactivity Percutaneous coronary intervention |
url |
http://link.springer.com/article/10.1186/s12933-019-0952-8 |
work_keys_str_mv |
AT annunziatanusca incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT dariotuccinardi incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT claudioproscia incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT rosettamelfi incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT silviamanfrini incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT antonionicolucci incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT antonioceriello incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT paolopozzilli incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT gianpaoloussia incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT francescogrigioni incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention AT germanodisciascio incrementalroleofglycaemicvariabilityoverhba1cinidentifyingtype2diabeticpatientswithhighplateletreactivityundergoingpercutaneouscoronaryintervention |
_version_ |
1724457252655464448 |